iRhythm/$IRTC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About iRhythm
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
Ticker
$IRTC
Sector
Primary listing
Employees
2,000
Headquarters
Website
iRhythm Metrics
BasicAdvanced
$5.5B
-
-$2.93
1.41
-
Price and volume
Market cap
$5.5B
Beta
1.41
52-week high
$187.57
52-week low
$55.92
Average daily volume
415K
Financial strength
Current ratio
5.022
Quick ratio
4.748
Long term debt to equity
693.019
Total debt to equity
708.802
Interest coverage (TTM)
-4.03%
Profitability
EBITDA (TTM)
-47.434
Gross margin (TTM)
69.78%
Net profit margin (TTM)
-14.06%
Operating margin (TTM)
-8.09%
Effective tax rate (TTM)
-0.90%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-3.53%
Return on equity (TTM)
-91.13%
Valuation
Price to revenue (TTM)
8.266
Price to book
53.33
Price to tangible book (TTM)
53.78
Price to free cash flow (TTM)
421.737
Free cash flow yield (TTM)
0.24%
Free cash flow per share (TTM)
0.408
Growth
Revenue change (TTM)
22.37%
Earnings per share change (TTM)
-31.26%
3-year revenue growth (CAGR)
22.03%
3-year earnings per share growth (CAGR)
-12.81%
What the Analysts think about iRhythm
Analyst ratings (Buy, Hold, Sell) for iRhythm stock.
Bulls say / Bears say
Q2 2025 revenue rose 26.1% year-over-year to $186.7 million, fueled by strong demand across core long-term monitoring, rising Zio AT adoption, and international market strength (GlobeNewswire)
Gross margin increased to 71.2% in Q2 2025, up 130 basis points from the previous year, indicating favorable volume leverage and operational efficiency improvements despite a higher-cost product mix (GlobeNewswire)
Established a strategic AI partnership with Lucem Health in Q2 2025 to advance early arrhythmia detection in high-risk groups, strengthening predictive care capabilities (GlobeNewswire)
Net loss remained at $14.2 million (–$0.44 per share) in Q2 2025 despite revenue growth, highlighting the company's continued lack of profitability (GlobeNewswire)
Adjusted operating expenses increased to $145.2 million in Q2 2025, up 16% year-over-year, reflecting sustained high investment levels that may weigh on short-term margins (GlobeNewswire)
Beginning January 1, 2025, CMS reduced the Medicare Physician Fee Schedule rate for CPT code 93229 (mobile cardiac telemetry), potentially lowering reimbursement for Zio AT services and negatively affecting revenue (SEC Filing)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
iRhythm Financial Performance
Revenues and expenses
iRhythm Earnings Performance
Company profitability
iRhythm News
AllArticlesVideos
Investor Short Report Flags Steep Downside Risk For iRhythm Technologies
Benzinga1 month ago
IRHYTHM INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of iRhythm Technologies, Inc. - IRTC
Business Wire2 months ago
IRHYTHM INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of iRhythm Technologies, Inc. - IRTC
Business Wire3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for iRhythm stock?
iRhythm (IRTC) has a market cap of $5.5B as of September 19, 2025.
What is the P/E ratio for iRhythm stock?
The price to earnings (P/E) ratio for iRhythm (IRTC) stock is 0 as of September 19, 2025.
Does iRhythm stock pay dividends?
No, iRhythm (IRTC) stock does not pay dividends to its shareholders as of September 19, 2025.
When is the next iRhythm dividend payment date?
iRhythm (IRTC) stock does not pay dividends to its shareholders.
What is the beta indicator for iRhythm?
iRhythm (IRTC) has a beta rating of 1.41. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.